AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 201 min read$PHIO

Plott Ronald Todd purchased $17K of PHIO

Plott Ronald Todd purchased 15,000 shares of Phio Pharmaceuticals Corp. (PHIO) at $1.14 on 2026-08-19.

Original reporting
SEC EDGAR · Plott Ronald Todd
Published Aug 20, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 12:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PHIO
Neutral
low confidence
Mentioned
$PHIO
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHIONeutralLow
01

Why it matters

The transaction is a routine insider purchase with limited market relevance.

02

Market read

Low relevance; small insider buy does not materially affect stock.

03

What to watch

Potential upcoming clinical data not reflected in this filing.

Relevance 4/10Novelty 3/10Timing: post‑market filing on Aug 20

Background

Form 4 filing discloses insider transactions to the SEC.

Company-level read

Ticker impact

$PHIONeutralLow confidence
Context

Director Plott Ronald Todd purchased 15,000 PHIO shares at $1.14 each, total $17,100.

Expected impact

Minimal impact; unlikely to move price.

Evidence & confidence

Purchase amount is tiny relative to market cap and typical trading volume.

Market effects

Sector

None; biotech sector unchanged.

Regional

None; US market only.

Global

None

Counterpoint

What could challenge this read

Even a small insider purchase could precede a positive catalyst.

Key entities

  • Company
    Phio Pharmaceuticals Corp.

    Biotech firm developing therapies.

  • Individual
    Plott Ronald Todd

    Director of PHIO.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PHIO insider trading history →

Related articles

AUG 6
$PHIOMedAI 8/10

Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Phio Pharmaceuticals (NASDAQ: PHIO) reported Q2 2026 results for the quarter ended June 30, 2026 and updated its PH-762 siRNA program. Cash fell to $13.0M from $21.0M at Dec. 31, 2025. R&D rose to $3.1M and net loss widened to $4.1M. PH-762 Phase 1b (22 patients) completed in March; FDA documentation is being prepared and an FDA meeting is planned for Q3 2026. The company also launched a $6.36M ATM equity program.

finanznachrichten.de7 min
AUG 6
$PHIOMed

Phio Pharmaceuticals Corp. (PHIO): Results of Operations and Financial Condition

Phio Pharmaceuticals Corp. (PHIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update Strategic milestone advancements for lead clinical candidate PH-762 Initiation of commercial scale API, long term non-clinical toxicology, completion of Phase 1b pharmacology, and

SEC EDGAR 8-K6 min
SEP 11
$DELLLow

Silver Lake Partners V DE (AIV), L.P. (Durban Egon) sold $14.9M of DELL (indirect holdings)

Silver Lake Partners V DE (AIV), L.P. sold 27,629 indirectly-held shares of Dell Technologies Inc. (DELL) at an average of $540.39 ($534.09–$550.71, $14.93M total) across 17 trades on 2026-09-09. Filed jointly with Silver Lake Technology Associates V, L.P. (Director), SLTA V (GP), L.L.C. (Director), Silver Lake Group, L.L.C. (Director) and Durban Egon (Director).

SEC EDGAR1 min
SEP 11
$DELLMed

Silver Lake Partners IV, L.P. (Durban Egon) sold $28.5M of DELL (indirect holdings)

Silver Lake Partners IV, L.P. sold 52,708 indirectly-held shares of Dell Technologies Inc. (DELL) at an average of $540.39 ($534.09–$550.71, $28.48M total) across 17 trades on 2026-09-09. Filed jointly with Silver Lake Technology Associates IV, L.P. (Director), SLTA IV (GP), L.L.C. (Director), Silver Lake Group, L.L.C. (Director) and Durban Egon (Director).

SEC EDGAR1 min